Flexion therapeutics, inc. (FLXN)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenues
Product revenue, net

20,127

23,654

21,786

16,953

10,564

9,543

6,990

3,797

2,194

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

Operating expenses
Cost of sales

2,276

3,928

2,872

1,398

1,762

2,073

1,619

946

2,698

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

21,134

17,072

20,938

16,125

15,424

14,856

13,578

13,094

11,551

15,860

12,846

11,769

10,756

11,381

9,047

8,905

11,981

8,967

7,829

9,640

6,255

5,499

4,658

3,614

4,150

2,236

2,569

3,067

3,186

Selling, general and administrative

29,299

32,248

32,136

33,103

32,222

30,572

32,804

31,036

26,899

32,267

18,375

15,133

13,026

10,171

8,388

5,215

4,692

4,511

3,197

2,904

2,760

2,241

2,304

2,234

2,283

1,341

2,420

1,422

1,520

Total operating expenses

52,709

53,248

55,946

50,626

49,408

47,501

48,001

45,076

41,148

48,131

31,221

26,902

23,782

21,552

17,435

14,120

16,673

13,478

11,026

12,544

9,015

7,741

6,962

5,848

6,434

3,577

4,990

4,490

4,707

Loss from operations

-32,582

-29,594

-34,160

-33,673

-38,844

-37,958

-41,011

-41,279

-38,954

-47,776

-31,221

-26,902

-23,782

-21,552

-17,435

-14,120

-16,673

-13,478

-11,026

-12,544

-9,015

-7,741

-6,962

-5,848

-6,434

-3,577

-4,990

-4,490

-4,707

Other (expense) income
Interest income

427

649

721

831

1,011

995

1,157

1,254

1,161

1,269

1,095

797

557

469

421

295

336

364

274

440

168

160

153

134

30

15

38

61

118

Interest expense

4,721

4,529

4,652

3,949

3,936

3,937

3,930

3,926

3,919

3,906

3,843

2,887

632

709

561

202

276

165

202

0

204

86

96

106

111

113

113

112

108

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

207

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

74

-42

-141

304

231

325

144

76

143

-121

-219

112

-22

-

-

-158

-202

-

-182

-332

-123

-137

-129

-110

-26

-14

-35

-56

-100

Total other (expense) income

-4,220

-3,922

-4,072

-2,814

-2,694

-2,617

-2,629

-2,596

-2,615

-2,758

-2,967

-1,978

-97

-1,560

-347

-65

-142

-91

-110

108

-159

-63

-73

-81

-107

-113

-110

-107

-90

Net loss

-36,802

-33,516

-38,232

-36,487

-41,538

-40,575

-43,640

-43,875

-41,569

-50,534

-34,188

-28,880

-23,879

-23,112

-17,782

-14,185

-16,815

-13,569

-11,136

-12,436

-9,174

-7,805

-7,035

-5,930

-6,542

-3,690

-5,100

-4,597

-4,798

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,100

-4,597

-4,798

Net loss per common share, basic and diluted

-0.95

-0.88

-1.00

-0.96

-1.09

-1.08

-1.15

-1.16

-1.10

-1.43

-1.07

-0.91

-0.75

-0.78

-0.65

-0.63

-0.78

-0.62

-0.52

-0.58

-0.43

-0.28

-0.45

-0.38

-0.86

-4.65

-6.46

-5.83

-6.08

Weighted average common shares outstanding, basic and diluted

38,553

38,217

38,125

38,010

37,992

37,869

37,818

37,697

37,620

36,647

31,931

31,826

31,704

29,428

27,524

22,666

21,570

21,555

21,507

21,475

21,451

16,698

15,624

15,619

7,632

792

789

789

789

Other comprehensive (loss) income:
Unrealized (losses) gains from available-for-sale securities, net of tax of $0

-56

-69

-99

125

182

80

153

266

-169

-346

18

-17

9

95

38

-18

-89

-100

9

-22

21

-5

-2

2

0

-1

0

-2

1

Total other comprehensive (loss) income

-56

-69

-99

125

182

80

153

266

-169

-346

18

-17

9

95

38

-18

-89

-100

9

-22

21

-5

-2

2

0

-1

0

-2

1

Comprehensive loss

-36,858

-33,585

-38,331

-36,362

-41,356

-40,495

-43,487

-43,609

-41,738

-50,880

-34,170

-28,897

-23,870

-23,017

-17,744

-14,203

-16,904

-13,669

-11,127

-12,458

-9,153

-7,811

-7,038

-5,928

-6,541

-3,691

-5,100

-4,600

-4,796